Intelligent Bio Solutions Inc. announced a private placement of 2,298,850 common shares (or pre-funded warrants) with attached Series K-1 and Series K-2 warrants to two healthcare-focused institutional investors, raising gross proceeds of $10.0 million. Each unit, comprised of one share (or pre-funded warrant) and warrants to purchase two additional shares, was priced at $4.35. The warrants carry a $4.10 exercise price, become exercisable immediately upon issuance, and have a five-year term following SEC declaration of an effective registration statement. Ladenburg Thalmann & Co. Inc. served as exclusive placement agent. The company expects to close the transaction on or about January 2, 2026, subject to customary conditions, and will deploy net proceeds for working capital and general corporate purposes.

Intelligent Bio Solutions entered into a strategic manufacturing agreement with Syrma Johari MedTech Ltd. to scale production of its Intelligent Fingerprinting Drug Screening Reader. Under the deal, annual production costs are projected to decrease by more than 40%, driving an anticipated 20-percentage-point improvement in gross margin compared with prior arrangements. Syrma Johari’s capacity—approximately four times INBS’s current output—will enable the company to meet growing demand as it expands into new regions and prepares for its planned U.S. market entry in 2026. The partnership, backed by multiple facilities across India, Europe and the U.S., strengthens supply-chain resilience and builds operational flexibility ahead of anticipated volume growth.